Interestingly, a recent study in pancreatic cancer cells showed that PLK1 inhibition enhances the effect of gemcitabine, also in gemcitabine‐resistant cells (Li et al., 2016). This evidence concerns the gene PLK1 and pancreatic neoplasm.